<DOC>
	<DOCNO>NCT01071018</DOCNO>
	<brief_summary>This study design evaluate safety tolerability , pharmacokinetics , pharmacodynamics anti-tumor activity MK2206 administer Every Other Day ( QOD ) Once Weekly ( QW ) dose schedule .</brief_summary>
	<brief_title>A Study MK2206 Locally Advanced Metastatic Solid Tumors ( 2206-007 )</brief_title>
	<detailed_description />
	<criteria>Patient must confirm locally advanced metastatic solid tumor fail respond standard therapy , gotten bad come back exist therapy Has adequate organ function Is ECOG Performance Scale 01 Has negative urine pregnancy test patient female Is able swallow capsule surgical bodily condition prevent patient swallow absorb oral medication ongoing basis Patient chemotherapy , radiotherapy , biological therapy surgery within 4 week start study recover adverse event cause treatment Is currently participate participate study investigational compound device within 28 day Has primary central nervous system tumor Has history current evidence heart disease , slow heart rate untreated high blood pressure Is know diabetic take insulin oral antidiabetic therapy Is pregnant breastfeed plan become pregnant study Is positive HIV antibody , HBs antigen HCV antibody</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>locally advanced metastatic solid tumor</keyword>
</DOC>